Nicotine & Metabolite
| Label Mnemonic: | NICOU |
| Epic code: | LAB414 |
| Downtime form: | A-1a Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Commercial Mailout Laboratory
6240-8 RCP
356-8593
6240-8 RCP
356-8593
Specimen(s):
Random Urine
Collection Medium:
) |
| Yellow top round bottom tube (no additive) |
Minimum:
Preferred Minimum: 4 mL random urine with no additives or
preservatives
Absolute Minimum: 1 mL random urine with no additives or preservatives
Absolute Minimum: 1 mL random urine with no additives or preservatives
Rejection Criteria:
Specimens exposed to repeated freeze/thaw cycles.
Turn Around
Time:
1-4 days upon receipt at reference laboratory
Reference Range:
Drugs Covered Cutoff Concentrations
Nicotine 15 ng/mL
Cotinine (metabolite) 15 ng/mL
3-OH-Cotinine (metabolite) 50 ng/mL
Anabasine (tobacco biomarker) 5 ng/m
Interpretive Data:
Drug and analytes covered: nicotine, cotinine (metabolite), 3-OH-
cotinine (metabolite), anabasine (tobacco biomarker). All drug and metabolites are the non-glucuronidated (free) form.
Positive cutoff:
Nicotine - 15 ng/mL
Cotinine - 15 ng/mL
3-OH-Cotinine - 50 ng/mL
Anabasine - 5 ng/mL
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
This test is designed to evaluate recent use of nicotine-containing products. Passive and active exposure cannot be discriminated definitively, although a cutoff of 100 ng/mL cotinine is frequently used for surgery qualification purposes. For smoking cessation programs or compliance testing, the absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Anabasine is included as a biomarker of tobacco use, versus nicotine replacement. Interpretive questions should be directed to the laboratory.
This test was developed and its performance characteristics determined by the reference laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Positive cutoff:
Nicotine - 15 ng/mL
Cotinine - 15 ng/mL
3-OH-Cotinine - 50 ng/mL
Anabasine - 5 ng/mL
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
This test is designed to evaluate recent use of nicotine-containing products. Passive and active exposure cannot be discriminated definitively, although a cutoff of 100 ng/mL cotinine is frequently used for surgery qualification purposes. For smoking cessation programs or compliance testing, the absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Anabasine is included as a biomarker of tobacco use, versus nicotine replacement. Interpretive questions should be directed to the laboratory.
This test was developed and its performance characteristics determined by the reference laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Comments:
Random urine collections acceptable.
Methodology:
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
CPT Code:
80323